A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment

The pharmacokinetics and safety of a single oral dose of 200‐mg plant‐derived pharmaceutical formulation of highly purified cannabidiol (CBD) in oral solution (Epidiolex in the United States; 100 mg/mL) were assessed in subjects with mild to severe hepatic impairment (n =  8 each for mild and modera...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Lesley, Crockett, Julie, Tayo, Bola, Morrison, Gilmour
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Editor's Choice: Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618279/
https://www.ncbi.nlm.nih.gov/pubmed/30921490
http://dx.doi.org/10.1002/jcph.1412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618279/
https://www.ncbi.nlm.nih.gov/pubmed/30921490
http://dx.doi.org/10.1002/jcph.1412

Ejemplares similares